Choreo LLC Makes New Investment in OPKO Health, Inc. (NASDAQ:OPK)

Choreo LLC purchased a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 70,000 shares of the biotechnology company’s stock, valued at approximately $106,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Invesco Ltd. grew its holdings in OPKO Health by 300.4% during the third quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock valued at $8,263,000 after purchasing an additional 3,874,519 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in OPKO Health by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 5,549,946 shares of the biotechnology company’s stock worth $8,880,000 after acquiring an additional 405,106 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in OPKO Health by 30.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,419,957 shares of the biotechnology company’s stock worth $2,272,000 after acquiring an additional 327,836 shares during the last quarter. Capula Management Ltd boosted its holdings in OPKO Health by 45.0% during the third quarter. Capula Management Ltd now owns 540,540 shares of the biotechnology company’s stock valued at $865,000 after acquiring an additional 167,860 shares during the period. Finally, Public Employees Retirement System of Ohio grew its position in shares of OPKO Health by 1,509.6% in the third quarter. Public Employees Retirement System of Ohio now owns 144,928 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 135,924 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 1,500,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average cost of $0.98 per share, for a total transaction of $1,470,000.00. Following the transaction, the chief executive officer now directly owns 207,368,225 shares in the company, valued at $203,220,860.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders bought 4,600,000 shares of company stock valued at $4,393,000. Corporate insiders own 47.26% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Barrington Research reaffirmed an “outperform” rating and set a $1.50 price objective on shares of OPKO Health in a research report on Monday, April 1st. Piper Sandler reissued an “overweight” rating and set a $5.00 price objective on shares of OPKO Health in a report on Monday, April 1st. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, April 3rd. Finally, StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Friday, March 1st.

OPKO Health Price Performance

OPKO Health stock opened at $1.30 on Friday. The business has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.22. OPKO Health, Inc. has a one year low of $0.85 and a one year high of $2.24. The company has a market capitalization of $906.09 million, a PE ratio of -5.20 and a beta of 1.81. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.55 and a quick ratio of 1.22.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The company had revenue of $181.90 million for the quarter, compared to the consensus estimate of $177.53 million. During the same quarter in the previous year, the company earned ($0.11) EPS. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, sell-side analysts forecast that OPKO Health, Inc. will post -0.33 EPS for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.